Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
295
Participants
Timeline
Start Date
March 17, 2014
Primary Completion Date
April 1, 2021
Study Completion Date
April 1, 2021
Conditions
Renal Cell CarcinomaMelanoma
Interventions
BIOLOGICAL
Pembrolizumab
IV infusion
BIOLOGICAL
PegIFN-2b
Subcutaneous infusion
BIOLOGICAL
Ipilimumab
IV infusion
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02089685 - Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | Biotech Hunter | Biotech Hunter